ICC 2023

BXQ-350 May Protect from the Direct Toxicity of Chemotherapeutic Agents Associated with Chemotherapy Induced Peripheral Neuropathy (CIPN)

Michael Gazda, Charles Cruze, Robin Furnish, Tim Stephens, Nikhil Wilkins, Gilles Tapolsky and Ray Takigiku

Bexxion PHARMACEUTICALS

1. Background:

- **Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side-effect associated** with many chemotherapeutic agents
- **CIPN is highly prevalent in CRC patients receiving therapeutic regimens including oxaliplatin;** ~15-20% of patients suffer from chronic CIPN that severely impacts quality of life (QoL) and may require dose vacation, dose reduction or treatment interruption
- **CIPN's pathology is complex** and not completely understood; preclinical and clinical data has shown **inflammatory (IL-6, Il-8, IL-10) and immune involvement as well as increased levels of sphingoisine-1-phosphate** (S1P), a bioactive signaling sphingolipid
- **Elevated S1P and dysregulated sphingolipid metabolism are associated with many diseases** including cancer, autoimmune, inflammatory, Gaucher and Parkinson diseases

2. BXQ-350 is a nanovesicle formulation of Saposin C, an allosteric activator of sphingolipid metabolism that normalizes dysregulated sphingolipid metabolism by lowering S1P and increasing ceramides levels



3. Methods: BXQ-350 was investigated in

- ***in vitro* and *in vivo* preclinical CIPN models (Point 4.)**
- **a Phase 1 dose escalation safety study in all-comer cancer patients** with recurrent solid malignancies (NCT02859857) **(Point 5.)**
  - BXQ-350 was **safe and well-tolerated** (no Dose Limiting Toxicity); a **17.8% Clinical Benefit Rate** (CR, PR, SD) was observed at Cycle 6 (**See Anti-Cancer Presentation**)
  - **One patient self-reported an improvement of their pre-existing CIPN symptoms** soon after BXQ-350 administration; this observation was confirmed in 4 out of 10 patients with established CIPN at the time of enrollment

Summary

- **BXQ-350 is a novel biologic** and a nanovesicle formulation of Saposin C, an allosteric activator of enzymes involved in sphingolipid metabolism
- BXQ-350 modulates sphingolipid metabolism**, lowers S1P and increases ceramide levels**
- BXQ-350 is **well-tolerated and showed signs of single agent activity in multiple cancer tumor types** in patients with recurrent advanced disease (**See Anti-Cancer Presentation**)
- In preclinical models, BXQ-350 **protects neuronal cells from oxaliplatin's neurotoxicity and prevents oxaliplatin-induced CIPN in mice**
- Clinically**, BXQ-350 seems to resolve CIPN symptoms in some cancer patients**

On-going Studies

Preclinical studies to illustrate BXQ-350's MOA.

BXQ-350 is clinically being investigated in:

- Phase 1/2 study in combination with SoC in newly diagnosed mCRC patients (NCT05322590)
- PoC and PK/PD study in cancer patients with established CIPN (NCT05291286)
- Phase 2 study in combination with radiation in pediatric DIPG/Diffuse Midline Glioma (NCT04771897)

Acknowledgement: Patients who participated in the trials and their families, clinicians and staff at investigational sites, Bexion's personnel

4. Preclinical Results:

BXQ-350 protects

- PC12 neuronal cells from chemotherapeutic agents' neurotoxicity and promotes neurite growth





- mice from oxaliplatin-induced CIPN in a murine mechanical allodynia model





5. Clinical Results:

- Pancreatic cancer patient (209) with history of grade 2 CIPN (oxaliplatin & nab-paclitaxel) spontaneously reported resolution of their symptoms by Cycle 2



- Patients with known CIPN symptoms at enrollment were *a posteriori* asked about their symptoms after receiving BXQ-350:
  - 4 out 10 patients appeared to have improvements of their symptoms following BXQ-350 administration
  - S1P levels decreased post BXQ-350 in 6 out 10 patients